TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...

Data from the first stage of a phase 3 study show significant reductions in proteinuria among patients treated with telitacicept.

UTIs have sneaky causes, many of which you can sidestep. Learn how habits like wearing a thong, cycling, and holding your pee ...

Trutakna (atacicept-vymj), a first-in-class dual BAFF and APRIL inhibitor, secured FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, supported by data ...

Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...